|
Market Cap (24-May) $66,720,148 (584th) |
Close (30-Jun) $0.040 |
Volume (30-Jun) 696,012 |
Shortsold (16-Jan) 98 (0.00%) (641st) |
|
52w High $0.099 |
52w Low $0.021 |
P/E 25.97 |
EPS 0 |
ACW released this announcement to the ASX on 24 February 2022, 12:50. The announcement is marked as price sensitive, and is 27 page(s) in length and 0.95MB in size.
You can view all announcements from ACW and see how they appear on a price chart on the announcements page.
At the date of this announcement, ACW was 0.078% short sold according to ASIC data. It was ranked the 492nd most shorted stock on the ASX. It remains ranked 641st as of the latest reported data (16 January 2025).
| Other Recent Announcements from ACW | |
|---|---|
| ACW CEO presentation on emerging oral Alzheimers therapies | 21 June 2023, 8:50 |
| ACW CEO & CMO present at BIO International Convention | 5 June 2023, 9:06 |
| ACW AD trial amendment and Clinical Science Forum slides | 24 May 2023, 8:20 |
| Appendix 4D & Half-Year Financial Statements | 24 February 2022, 12:50 |
| Actinogen appoints Prof Paul Rolan as Chief Medical Officer | 15 February 2022, 9:26 |
| Actinogen XanaMIA Part A trial results expected in April | 11 February 2022, 9:32 |
| Actinogen appoints XanaFX Phase 2 trial manager | 9 February 2022, 9:44 |
You must be logged in to post a reply.
Actinogen Medical 